文献速递乳腺癌

晚期乳腺癌中循环肿瘤细胞计数驱动治疗选择的总体生存:一项随机试验

Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial.
PubMed 文献 · J Clin Oncol · 2023-11-06

STIC CTC试验在激素受体阳性、HER2阴性晚期乳腺癌患者中比较循环肿瘤细胞(CTC)计数与研究者选择指导一线治疗。中位随访4.7年,755例中382例死亡,CTC组中位OS 51.3个月 vs 标准组45.5个月(HR 0.85,95%CI 0.69-1.03,P=.11)。在临床医生推荐内分泌治疗但CTC高的189例患者中,化疗优于内分泌治疗(HR 0.53,95%CI 0.36-0.78,P=.001)。

要点

  • CTC计数指导治疗与研究者选择相比,总生存无显著差异(HR 0.85,95%CI 0.69-1.03,P=.11)。
  • 临床医生推荐内分泌治疗但CTC≥5/7.5mL者,化疗较内分泌治疗改善生存(HR 0.53,95%CI 0.36-0.78,P=.001)。
  • CTC计数在内分泌与化疗选择不一致时显示出临床实用价值。

核心结论

  • 在激素受体阳性、HER2阴性晚期乳腺癌中,CTC计数指导一线治疗选择与研究者选择相比,总生存无显著差异。
  • 在临床医生推荐内分泌治疗但CTC计数高的患者中,化疗较内分泌治疗显著改善总生存。
  • 当内分泌治疗与化疗的估计不一致时,总生存数据证明CTC计数具有临床实用价值。

研究设计与样本

  • STIC CTC试验为随机试验,患者按1:1随机分配至研究者选择或CTC计数指导一线治疗(内分泌治疗或化疗)。
  • CTC计数≥5个/7.5mL时选择化疗,CTC计数低时选择内分泌治疗,检测方法为CellSearch。
  • 共纳入755例患者,中位随访4.7年,发生382例死亡(50.6%)。

主要发现

  • CTC组中位总生存为51.3个月(95%CI 46.8-55.1),标准组为45.5个月(95%CI 40.9-51.1),死亡风险比HR 0.85(95%CI 0.69-1.03,P=.11)。
  • 在189例(25.0%)临床医生推荐内分泌治疗且CTC计数高的患者中,化疗较内分泌治疗改善总生存(HR 0.53,95%CI 0.36-0.78,P=.001)。

关键数值与推荐

  • CTC计数指导组:CTC≥5个/7.5mL时选择化疗,CTC计数低时选择内分泌治疗。
  • CTC组中位总生存51.3个月(95%CI 46.8-55.1) vs 标准组45.5个月(95%CI 40.9-51.1)。
  • 临床医生推荐内分泌治疗且CTC高者:化疗 vs 内分泌治疗的死亡HR 0.53(95%CI 0.36-0.78,P=.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.In patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, the STIC CTC trial established that, for choosing between endocrine therapy (ET) or chemotherapy, the use of circulating tumor cell (CTC) count is noninferior to the investigator's choice in terms of progression-free survival. Here, we report overall survival (OS) results, a secondary end point. Patients were randomly assigned in a 1:1 ratio to have their first-line treatment (ET or chemotherapy) determined by investigators or CTC count (chemotherapy if ≥ 5 CTCs/7.5 mL; ET if low CTC count; CellSearch). OS was assessed at the discontinuation of follow-up. After a median follow-up of 4.7 years, 382 deaths (50.6%) had occurred among 755 patients. Median OS was 51.3 months (95% CI, 46.8 to 55.1) in the CTC arm and 45.5 months (95% CI, 40.9 to 51.1) in the standard arm (hazard ratio [HR] for death, 0.85; 95% CI, 0.69 to 1.03; P = .11). Among 189 patients (25.0%) with ET recommended by clinicians and high CTC count, chemotherapy was superior to ET (HR for death, 0.53; 95% CI, 0.36 to 0.78; P = .001). In case of a discordant estimate, OS data demonstrate the clinical utility of CTC count.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bidard FC, Kiavue N, Jacot W, et al. Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized Trial. J Clin Oncol. 2023. PMID: 37931185. doi:10.1200/JCO.23.00456

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。